EUVIMEDEUVIMED entdecken
Crossref

Characterization of the Systemic Effects of Casiopeina III‐Ia Using an In Vivo Glioma Model: Antitumoral, Pharmacokinetics, and Immune Responses

Cristina Trejo-Solís, Inés Fuentes-Noriega, Alma Ortiz-Plata, Benjamín Pineda, Alejandro Macario-Hernández, Rosa Angelica Castillo-Rodriguez, Francisca Palomares-Alonso, Antonio Romo-Mancillas iD, Daniela Silva Adaya, Lena Ruiz-Azuara, Dolores Jiménez-Farfán, Juan Carlos García-Ramos iD

Archiv der Pharmazie · 2025

DOI: 10.1002/ardp.70132 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, 2025. Verfasst von Cristina Trejo-Solís und 11 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio Experimental de Enfermedades Neurodegenerativas, Laboratorio de Patología Experimental, Laboratorio de Neuroinmunología, Laboratorio de N…. Hauptthemen laut MEDLINE: Glioma, Antineoplastic Agents, Brain Neoplasms. Die Arbeit nennt 95 Literaturangaben. Gefördert von: The authors thank Consejo Nacional de Humanidades, Ciencia y Tecnología, for financial support for this Project, grant number U41997-MA1..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The antineoplastic properties of the Cu(II) coordination compound Casiopeina III‐ia (Cas III‐ia) are revealed using an in vivo glioma model, and its biopharmaceutical properties are predicted through an in silico analysis. C6 cells of the murine glioma allograft model were implanted in rats to form glioma tumors and treated with Cas III‐ia at doses of 0.75 and 1.5 mg/kg/day for 21 days. The mean tumor volume of treated rats was reduced by 73% and 88% compared with the control, respectively. Moreover, the mitotic and proliferation indexes decreased with a simultaneous increase in the apoptotic index. We observed the generation of reactive oxygen species, lipoperoxidation, increased p21WAF/CIP, Bax, cleaved caspase 3, and decreased Cyclin D and Bcl‐2. The pharmacokinetic study reveals a half‐life of 12.4 h, depuration of 5.3 mL/h, and a volume of distribution of Cas III‐ia of 20.3 L. In silico analysis revealed that Cas III‐ia possesses potential oral bioavailability, high gastrointestinal absorption, the capacity to penetrate the blood–brain barrier, and is a potential target of glycoproteins, but not a substrate of CYP1A2, CYP2C19, CYP2C9, CYP2D6, and CYP3A4. Our findings strongly suggest that Cas III‐ia holds excellent promise as a potential compound for treating human malignant glioma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GliomaAntineoplastic AgentsBrain NeoplasmsAnimalsRatsMaleCell Line, TumorMiceApoptosisCell ProliferationDose-Response Relationship, DrugDisease Models, AnimalBiological AvailabilityHalf-LifeStructure-Activity RelationshipReactive Oxygen Species

Stichwörter der Autor:innen

Cu(II) compoundantitumor effectapoptosisglioma C6reactive oxygen species

Substanzen

Antineoplastic AgentsReactive Oxygen Species

Autor:innen und Institutionen

  • Laboratorio Experimental de Enfermedades Neurodegenerativas, Laboratorio de Patología Experimental, Laboratorio de Neuroinmunología, Laboratorio de Neuropsicofarmacología, Instituto Nacional de Neurología y Neurocirugía…
  • Departamento de Farmacia, Facultad de Química, Universidad Nacional Autónoma de México, Ciudad de México, Mexico.
  • Laboratorio de Inmunología, Posgrado de Odontología, Universidad Nacional Autónoma de México, Ciudad de, Mexico.
  • CICATA Unidad Morelos, Instituto Politécnico Nacional. Atlacholoaya, Morelos, México.
  • Laboratorio de Diseño Asistido por Computadora y Síntesis de Fármacos, Facultad de Química, Universidad Autónoma de Querétaro, Centro Universitario, Querétaro, Mexico.
  • Departamento de Química Inorgánica y Nuclear, Facultad de Química, Universidad Nacional Autónoma de México, Ciudad de México, Mexico.

ORCID-Profile: Antonio Romo-Mancillas, Juan Carlos García-Ramos

Förderung

  • The authors thank Consejo Nacional de Humanidades, Ciencia y Tecnología, for financial support for this Project, grant number U41997-MA1.

Zitieren

APA

Trejo-Solís, C., Fuentes-Noriega, I., Ortiz-Plata, A., Pineda, B., Macario-Hernández, A., Castillo-Rodriguez, R. A., Palomares-Alonso, F., Romo-Mancillas, A., Adaya, D. S., Ruiz-Azuara, L., Jiménez-Farfán, D., & García-Ramos, J. C. (2025). Characterization of the Systemic Effects of Casiopeina III‐Ia Using an In Vivo Glioma Model: Antitumoral, Pharmacokinetics, and Immune Responses. Archiv der Pharmazie. https://doi.org/10.1002/ardp.70132

Vancouver

Trejo-Solís C, Fuentes-Noriega I, Ortiz-Plata A, Pineda B, Macario-Hernández A, Castillo-Rodriguez RA, et al. Characterization of the Systemic Effects of Casiopeina III‐Ia Using an In Vivo Glioma Model: Antitumoral, Pharmacokinetics, and Immune Responses. Archiv der Pharmazie. 2025. doi:10.1002/ardp.70132

BibTeX
@article{TrejoSols2025,
  author = {Trejo-Solís, Cristina and Fuentes-Noriega, Inés and Ortiz-Plata, Alma and Pineda, Benjamín and Macario-Hernández, Alejandro and Castillo-Rodriguez, Rosa Angelica and Palomares-Alonso, Francisca and Romo-Mancillas, Antonio and Adaya, Daniela Silva and Ruiz-Azuara, Lena and Jiménez-Farfán, Dolores and García-Ramos, Juan Carlos},
  title = {Characterization of the Systemic Effects of Casiopeina III‐Ia Using an In Vivo Glioma Model: Antitumoral, Pharmacokinetics, and Immune Responses},
  journal = {Archiv der Pharmazie},
  year = {2025},
  doi = {10.1002/ardp.70132}
}
Kostenlos starten →